Industrial biotechnology: Enabling sustainable and scalable biopharmaceutical manufacturing

With the rising demand for bio-based solutions (1), industrial biotechnology now plays an increasingly important role as a foundational manufacturing platform in the biopharmaceutical industry. By utilising biological systems such as microorganisms (bacteria, yeast, fungi) or enzymes, it enables the efficient production of active pharmaceuticals ingredients, intermediates, excipients and biologics at an industrial scale. Compared to traditional petroleum-based chemical production, biotechnology uses less energy and generates less waste and greenhouse gas emissions.

While industrial biotechnology has long been established in food enzymes and bioethanol sectors (2), the field has evolved significantly in recent years. At the core of this evolution is industrial fermentation, which translates biological innovation into scalable manufacturing reality. The advancements in fermentation engineering and enzyme engineering are improving the capability to scale, enhance efficiencies, and enable the effectiveness of industrial biotechnology (3). Through controlled cultivation of microorganisms, fermentation serves as the primary production backbone for many biology-driven processes, providing the efficiency and scalability required for biopharmaceutical processing.

The growing awareness regarding the environmental impact of industrial operations has created a shift towards a more sustainable approach. Industrial biotechnology supports this transition by enabling cleaner production processes with significantly reduced environmental footprints. Compared to conventional methods, the biology-driven process demands less water consumption and lower energy requirements while minimising the use of harmful solvents (4).

Beyond environmental conditions, industrial biotechnology, supported by fermentation-based production, plays an important role in strengthening supply chain resilience. Conventional manufacturing is dependent on petrochemical feedstocks and geographically concentrated supply chains, exposing manufacturers to price volatility and disruption risks.

As industrial biotechnology and fermentation continue to shape the future of biopharmaceutical manufacturing, reliable upstream and downstream solutions are required to enable consistent performance and scalable production.

In upstream operations, fermentation culture media, bioprocess nutrients, enzymes, buffers and reagents support cell growth and consistent fermentation performance while downstream solutions such as chromatography resins, process chemicals and solvents play a critical role in achieving the required purity and quality standards. Cryopreservation media and additives support long-term process continuity, and together, these provide the foundation that enables scalable and reliable biopharma manufacturing.  

IMCD Pharmaceuticals supports fermentation-based bioprocess across upstream, downstream, and cell handling stages to support manufacturers across the bioprocessing lifecycle. By working closely with our trusted global partners, we combine technical expertise, high-quality ingredients, and application know-how to help manufacturers build resilient, scalable, and compliant biopharmaceutical processes.